CIRM Funded Clinical Trials

Autologous ARTEMISĀ® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

Disease Area:
Investigator:
CIRM Grant:
CLIN2-14338 (Active)
Award Value:
$10,600,072.00
Trial Sponsor:
Eureka Therapeutics, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov